TuHURA Biosciences (HURA)
Develops immunotherapies aimed at overcoming resistance to cancer treatment.
Something off on this page? Send us feedback.
Develops clinical-stage immuno-oncology candidates centered on its IFx platform. Its lead IFx-2.0 program is in a registration trial, while TBS-2025 broadened the pipeline through the Kineta acquisition.
Develops clinical-stage immuno-oncology candidates designed to address primary and acquired resistance to cancer immunotherapies. The IFx platform is central to the portfolio, with lead candidate IFx-2.0 in a Phase 3 registration trial with pembrolizumab for first-line advanced or metastatic Merkel cell carcinoma. It is an innate-immune agonist intended to address primary resistance to checkpoint inhibitors.
Pipeline scope expanded with TBS-2025, a VISTA-inhibiting monoclonal-antibody program acquired from Kineta. The company has no marketed products, and its business is shaped by clinical development and the ability of its candidates to address resistance to cancer immunotherapy.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $996.0K · Total debt $407.0K · Total assets $31.7M · Shareholders' equity $18.5M
- Revenue
- $0
- Operating income
- −$8.8M
- Net income
- −$9.2M
No dividends on record.
| Institutions89 holders · as of Mar 31, 2026 | 14.92% | 9.51M shares | |
| Insiders1 holder · as of May 29, 2026 | 3.41% | 2.17M shares | |
| Strategic holders1 holder · as of Feb 17, 2026 | 9.51% | 6.06M shares | |
| Otherremainder | 72.16% | 45.98M shares |
63.73M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Highbridge Capital Management, LLCStrategic | 9.51% | 6.06M | 13Gfiled Feb 17, 2026 ↗ |
BlackRock, Inc.Institution | 3.84% | 2.45M | 13Fas of Mar 31, 2026 |
James A. Bianco1Insiderdirector, officer: Chief Executive Officer | 3.41% | 2.17M | Form 4filed May 29, 2026 ↗ |
Vanguard Capital Management LLCInstitution | 3.25% | 2.07M | 13Fas of Mar 31, 2026 |
Geode Capital Management, LLCInstitution | 1.55% | 986,922 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Reported at 4.60% on Aug 28, 2026, under the 5% line, so no further filing is required.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Pfizer
BAVENCIO is an approved PD-L1 therapy for metastatic MCC
- Merck
KEYTRUDA is approved PD-1 therapy and the IFx-2.0 trial backbone
- Incyte
ZYNYZ is an approved PD-1 therapy for advanced or recurrent MCC
- Kura
KOMZIFTI is an approved menin inhibitor for NPM1-mutated R/R AML
- Syndax Pharmaceuticals
REVUFORJ is an approved menin inhibitor for NPM1-mutated R/R AML
- Replimune Group
Oncolytic immunotherapy paired with PD-1 blockade in advanced melanoma
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TuHURA Biosciences | $2.08 | +2.46% | $133.1M | — | — | — | — |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Merck | $151.14 | −0.33% | $374.52B | 121.3 | 17.6 | 5.6 | +5.1% |
| Incyte | $128.82 | +3.05% | $26.11B | 16.4 | 53.4 | 4.5 | +37.7% |
| Kura | $13.58 | +3.62% | $1.16B | — | — | 15.1 | +36.5% |
| Syndax Pharmaceuticals | $20.79 | +3.43% | $1.84B | — | — | 7.3 | +91.8% |
| Replimune Group | $15.90 | −0.50% | $1.34B | — | — | — | — |
| Median | 38.3 | 17.6 | 5.6 | +36.5% |